Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Addition of Darolutamide to First Line Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06401980Phase 2Recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Oct 2024
- Primary completion
- Jun 2030
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Swiss Group for Clinical Cancer Research. Started Oct 2024; status: recruiting.
02
Drugs
darolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06401980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06401980.